高级搜索
L-OHP、DOC和HCPT联合5-Fu序贯化疗治疗晚期胃癌的临床研究[J]. 肿瘤防治研究, 2013, 40(03): 261-263. DOI: 10.3971/j.issn.1000-8578.2013.03.010
引用本文: L-OHP、DOC和HCPT联合5-Fu序贯化疗治疗晚期胃癌的临床研究[J]. 肿瘤防治研究, 2013, 40(03): 261-263. DOI: 10.3971/j.issn.1000-8578.2013.03.010
Clinical Observation of Sequential Chemotherapy in Advanced Gastric Cancer with Oxaliplatin Docetaxel and Hydroxy Camptothecine Plus 5-fluorouracil[J]. Cancer Research on Prevention and Treatment, 2013, 40(03): 261-263. DOI: 10.3971/j.issn.1000-8578.2013.03.010
Citation: Clinical Observation of Sequential Chemotherapy in Advanced Gastric Cancer with Oxaliplatin Docetaxel and Hydroxy Camptothecine Plus 5-fluorouracil[J]. Cancer Research on Prevention and Treatment, 2013, 40(03): 261-263. DOI: 10.3971/j.issn.1000-8578.2013.03.010

L-OHP、DOC和HCPT联合5-Fu序贯化疗治疗晚期胃癌的临床研究

Clinical Observation of Sequential Chemotherapy in Advanced Gastric Cancer with Oxaliplatin Docetaxel and Hydroxy Camptothecine Plus 5-fluorouracil

  • 摘要: 目的 探讨奥沙利铂(oxaliplatin,L-OHP)、多西紫杉醇(docetaxel,DOC)和羟基喜树碱(hydroxy camptothecine,HCPT)联合5-氟尿嘧啶(5-Fluorouracil,5-Fu)/亚叶酸钙(calcium folinate,CF)组成的序贯化疗方案治疗晚期胃癌(advanced gastric cancer,AGC)的疗效和不良反应。方法入组35例AGC患者,以序贯方式依次接受L-OHP+5-Fu/CF、DOC+5-Fu/CF和HCPT+5-Fu/CF方案化疗,每个方案连用2周期,均每3周重复,共6周期化疗;观察疗效和不良反应,并随访疾病进展情况。结果35例均能评价疗效,总缓解率(RR)为60%(21/35),中位肿瘤进展时间(TTP)为7.6月,95%置信区间(CI)(7.0~8.2),中位生存期(OS)15.1月,95% CI (14.2~16.0);不良反应程度较轻,主要为骨髓抑制、胃肠道反应、脱发及过敏反应,但均可逆,未出现因化疗毒性而死亡病例。结论L-OHP、DOC和HCPT联合5-Fu/CF的序贯化疗是AGC有效治疗方案,化疗耐受性好,新颖的序贯化疗模式在AGC中应用值得进一步研究。

     

    Abstract: Objective To observe the efficacy and adverse reaction of sequential chemotherapy consists of oxaliplatin,docetaxel and hydroxy camptothecine plus 5-fluorouracil to advanced gastric cancer(AGC). Methods Thirty-five patients were all treated with chemotherapy of L-OHP+5-Fu/CF,DOC+5-Fu/CF and HCPT+5-Fu/CF in sequence,every chemotherapy regimen was used continuously 2 cycles and repeated every 21 days.All patients received 6 cycles totally.Efficacy and toxicity were evaluated. Results The clinical efficacy has been evaluated in all 35 patients.The whole response rate(RR)was 60%(21/35),the median time to progression (TTP) was 7.6 months,95% confidence interval(CI)ranged 7.0-8.2 months,the median overall survival(OS)was 15.1 months,95% CI ranged 14.2-16.0 months.The major toxic reactions included marrow suppression,nausea,vomiting,alopecia and allergic reactions,but all of them are reversible.No patients were dead from toxic reactions of chemotherapy. Conclusion The sequential chemotherapy of L-OHP,DOC and HCPT plus 5-Fu is an effective and tolerable regimen for AGC.The innovative chemotherapy schema deserves clinical expansion and further exploration in the future.

     

/

返回文章
返回